Determining joint carrier probabilities of cancer‐causing genes using Markov chain Monte Carlo methods

In genetic counseling for cancer risk, the probability of carrying a mutation of a cancer‐causing gene plays an important role. Family history of various cancers is important in calculating this probability. BRCAPRO (Parmigiani et al. [1998] Am J Hum Genet 62:145–158) is a widely used software for calculating the probability of carrying mutations in BRCA1 and BRCA2 genes given the family history of breast and ovarian cancer in first‐ and second‐degree relatives. BRCAPRO uses an analytical (exact) calculational procedure. Using Markov chain Monte Carlo (MCMC) methods, we extend BRCAPRO to handle, in principle, any type of cancer, family history, any number of genes and alleles that each gene may have. When the information used in this MCMC approach is the same as for BRCAPRO (two genes: BRCA1 and BRCA2; two cancers: breast and ovarian; first‐ and second‐degree relatives only), the two approaches give essentially the same answer. Extending the model to include (1) prostate cancer, (2) two mutated alleles of BRCA2, namely, mutations in Ovarian Cancer Cluster Region (OCCR) and non‐OCCR region, and (3) relatives of degree greater than second‐degree, leads to different carrier probabilities. The MCMC approach is a useful tool in building a comprehensive model to give accurate estimates of carrier probabilities. Such an approach will be even more important as additional information about the genetics of various cancers becomes available. Genet. Epidemiol. 2005. © 2005 Wiley‐Liss, Inc.

[1]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[2]  N. Risch,et al.  Autosomal dominant inheritance of early‐onset breast cancer. Implications for risk prediction , 1994 .

[3]  Giovanni Parmigiani,et al.  BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  B. Rosen,et al.  Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. , 2001, American journal of human genetics.

[5]  H. Nevanlinna,et al.  A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families , 2001, British Journal of Cancer.

[6]  Walter R. Gilks,et al.  Gibbs sampling methods in genetics , 1995 .

[7]  S Wacholder,et al.  The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. , 1999, American journal of human genetics.

[8]  D. Berry,et al.  Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. , 1997, Journal of the National Cancer Institute.

[9]  S Lin,et al.  An algorithm for Monte Carlo estimation of genotype probabilities on complex pedigrees , 1994, Annals of human genetics.

[10]  D. Easton,et al.  Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. , 2001, American journal of human genetics.

[11]  B. Karlan,et al.  Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Easton,et al.  The BOADICEA model of genetic susceptibility to breast and ovarian cancer , 2004, British Journal of Cancer.

[13]  F. Couch,et al.  BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. , 1997, The New England journal of medicine.

[14]  Douglas F Easton,et al.  Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.

[15]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[16]  H. Olsson Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.

[17]  Donald A. Berry,et al.  Genetic Susceptibility and Survival: Application to Breast Cancer , 2000 .

[18]  N. Carson,et al.  A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center , 2000, Clinical genetics.

[19]  N E Day,et al.  A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes , 2002, British Journal of Cancer.

[20]  D. Berry,et al.  Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. , 1998, American journal of human genetics.

[21]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[22]  S. Cummings,et al.  Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  B. Ponder,et al.  Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. , 2003, American journal of human genetics.